Detect Earlier for Greater Drug Safety
Webinar: High Sensitivity Measurement of Immunogenicity is Important for Patient Safety
Detecting immunogenicity and anti-drug antibodies (ADA) earlier in the drug discovery process requires levels of sensitivity that Single Molecule Counting (SMC™) technology can provide.
The impact of early ADA detection and the clinical effects of these responses may affect a drug's pharmacokinetics, pharmacodynamics, safety, and efficacy. To learn more about this technology, attend our Nature webinar, High Sensitivity Measurement of Immunogenicity is Important for Patient Safety, where our expert in the field of immunoassay technology will deliver an engaging overview on how the SMC™ platform can improve assay sensitivity for earlier ADA detection and increase drug safety.
Date: Thursday, November 14th, 2019
Time: 8AM PST | 11AM EST | 4PM GMT | 5PM CET
Duration: 60 minutes
Presented by: Daniel Garcia-West, Scientist and Field Marketing Specialist at Merck KGaA, Darmstadt, Germany
Interested in speaking with our immunoassay experts? Come visit us on October 15th-18th at the Immunogenicity & Bioassay Summit in Washington DC at booth #2. For more information on SMC™ technology and immunogenicity testing, please visit our website and discover numerous application notes, posters and additional resources to support your research at every step.
[Webinar] Improved Immunogenicity Detection for Greater Drug Safety